Source: Acrofan

CANbridge: CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

Read full article »
CANbridge's Competitors | CANbridge's News | CANbridge's Financials
Stay up-to-date with the latest news on CANbridge
Annual Revenue
$5.0-25M
Employees
1-25
James Xue's photo - Chairman & CEO of CANbridge

Chairman & CEO

James Xue

CEO Approval Rating

89/100

Read more
Stay up-to-date with the latest news on CANbridge